The Claim

Oral obicetrapib at 10 mg daily for 12 months reduces the 12-month increase in plasma phosphorylated tau-217 by 2.84% compared to placebo in adults with atherosclerotic cardiovascular disease, with a 20.48% reduction in the increase of plasma phosphorylated tau-217 relative to placebo observed in ApoE4/E4 homozygotes.

Source: Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Taking 10 mg of obicetrapib daily for one year reduces the rise in a blood biomarker called phosphorylated tau-217 by 2.84% compared to a placebo in adults with atherosclerotic cardiovascular disease. In individuals with two copies of the ApoE4 gene, the reduction in biomarker increase is 20.48% compared to placebo.

See the scientific wording

Oral obicetrapib at 10 mg daily for 12 months significantly reduces the 12-month increase in plasma phosphorylated tau-217 by 2.84% compared to placebo in adults with atherosclerotic cardiovascular disease, with the greatest effect observed in ApoE4/E4 homozygotes, where it prevents a 20.48% increase relative to placebo, suggesting a direct biological impact on a key Alzheimer’s disease biomarker pathway.

Why this might work

A pill blocks a protein that normally moves cholesterol between blood fats, causing good cholesterol particles to grow smaller and more numerous. These small particles enter the brain, remove excess cholesterol and toxic fats from brain support cells, and bring in protective antioxidants. This clears away harmful buildup and stops a key brain protein from becoming abnormally modified, which is linked to memory decline.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

    Taking this pill called obicetrapib for a year slowed down the rise of a brain protein linked to Alzheimer’s, especially in people with two copies of a gene that raises Alzheimer’s risk — in fact, it made the protein go down in this group while it went up in those who took a dummy pill.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.